Radiotherapy & Combi in Metastatic Melanoma

NCT02392871 | Completed Phase 1 DMC

• 1 other identifier: 02.14
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to investigate the side effects and safety, and effectiveness of combining dabrafenib and trametinib with radiotherapy. Previous and ongoing clinical trials have demonstrated the effectiveness and safety of combining both dabrafenib and trametinib compared with dabrafenib alone. This has led to the approval for the use of both drugs in combination in people with metastatic melanoma with the BRAF mutation. Melanoma that has spread to other parts of the body may also benefit from radiotherapy to help reduce symptoms from melanoma. Previous studies have shown that melanoma may be sensitive to radiotherapy and that it can help to improve quality of life. The intention of the CombiRT study is to establish if dabrafenib, trametinib and radiotherapy combined is a safe and effective treatment for metastatic melanoma.

Conditions

Metastatic Melanoma

Keywords

Metastatic melanoma; Palliative radiotherapy

Outcome Measures

Primary Outcomes (1)

• Toxicity profile for patients receiving dabrafenib and trametinib in combination with RT, by measuring adverse events and radiotherapy associated toxicities.

  0-12 months

Secondary Outcomes (4)

• Patients' pain using a visual analog scale (questionnaire)

  0-12 months

• Overall disease response by measuring progression free survival and overall survival.

  0-12 months

• Local treatment response in the irradiated index lesion(s).

  0-12 months

• Time to local progression in the irradiated index lesion(s).

  0-12 months

Study Arms (1)

Radiotherapy

EXPERIMENTAL

Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma. Palliative RT will be delivered to symptomatic or bulky (\>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time. Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria.

Radiation: Palliative radiotherapy; Drug: Dabrafenib and trametinib (combination)

Interventions

Palliative radiotherapy RADIATION

Radiotherapy

Dabrafenib and trametinib (combination) DRUG

Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.

Radiotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥18 years of age.
• Signed written informed consent.
• Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive as determined by a BRAF mutation assay.
• Note: For Stage IIIC disease, the decision that the disease is unresectable should be formally endorsed by the melanoma multidisciplinary tumour board of the local institution.
• Have received dabrafenib and trametinib for 2 weeks or more prior to enrolment in the study (i.e. first fraction of palliative RT), and is still continuing with dabrafenib and trametinib.
• Symptomatic or bulky (greater than 2 cm in diameter) soft tissue, nodal or bony metastases requiring palliative RT.
• Have measurable disease according to RECIST 1.1 criteria. Note: patients with bony metastases that are not measurable by RECIST 1.1 criteria are allowed in this study.
• All anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed on Table 1 in protocol) must be less than or equal to (≤) Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03; NCI, 2009) at the time of study enrolment.
• Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
• Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrolment and agree to use effective contraception, from 14 days prior to enrolment throughout the treatment period, and for 4 months after the last dose of study treatment.
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate baseline organ function (as defined in Table 1 in protocol).

You may not qualify if:

• Treatment with Ipilimumab or any other anti-CTLA-4 monoclonal antibody therapy within the past 4 weeks.
• Treatment with anti-PD-1 or anti-PD-L1 monoclonal antibody therapy within the past 4 weeks.
• Known ocular or primary mucosal melanoma.
• Four (4) or more lesions requiring palliative RT at the time of study enrolment.
• Symptomatic brain metastases or those treated \< 3 months previously.
• Clear evidence of systemic disease progression on dabrafenib and trametinib.
• Systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within the last 4 weeks. Prior interferon treatment in the adjuvant setting is allowed.
• Note: Tamoxifen and aromatase inhibitors are allowed in the adjuvant setting of breast cancer.
• Current use of a prohibited medication (list of prohibited medications in protocol).
• History of malignancy other than disease under study within 3 years of study enrolment with exceptions below, or any malignancy with confirmed activating RAS mutation.
• Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.
• Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer.
• Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures.
• A history of known Human Immunodeficiency Virus (HIV).
• A history or evidence of cardiovascular risk including any of the following:

Sponsors & Collaborators

• Melanoma and Skin Cancer Trials Limited: lead
• Melanoma Institute Australia: collaborator

Study Sites (3)

St Vincent's Hospital

Darlinghurst, New South Wales, 2010, Australia

Location

Westmead Hospital

Sydney, New South Wales, 2145, Australia

Location

Princess Alexandra Hospital

Brisbane, Queensland, 4102, Australia

Location

MeSH Terms

Conditions

Melanoma

Interventions

dabrafenib; trametinib

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Tim Wang

  Westmead Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2015
• First Posted: March 19, 2015
• Study Start: May 1, 2015
• Primary Completion: September 23, 2019
• Study Completion: April 17, 2020
• Last Updated: November 27, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

AU (3)